Abstract

Propylthiouracil 5 mg/mL in SyrSpend SF pH4

Author(s): Allen Loyd V Jr

Issue: Mar/Apr 2020 - Volume 24, Number 2

Page(s): 135

Download in electronic PDF format for $75
  • Propylthiouracil 5 mg/mL in SyrSpend SF pH4 Page 1

Abstract

A formulation for preparing Propylthiouracil 5 mg/mL in SyrSpend SF pH4. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • propylthiouracil
  • formulation
  • stability
  • storage temperature
  • antithyroid agent
  • thryoid disorders
  • hyperthyroidism
  • thiocarbamide compound

Related Categories

  • EXCIPIENTS
  • FORMULATIONS
  • ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2020
Pg. 135
Propylthiouracil 5 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Jul/Aug 2017
Pg. 339-346
Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4
Author(s): de Oliveira Ferreira Anderson, Polonini Hudson, Loures da Silva Sharlene, Buzinari Aglio Natália Cristina, Abreu Jordana, Fernandes Brandão Marcos Antônio
Jul/Aug 2001
Pg. 310-312
Wetting and/or Solubilizing Agents, Featured Excipient:
Author(s): Allen Loyd V Jr
Jan/Feb 2006
Pg. 67
Propylthiouracil 5-mg/mL Oral Liquid
Author(s): Allen Loyd V Jr
Nov/Dec 2004
Pg. 462-465
Basics of Compounding for Cough
Author(s): Allen Loyd V Jr
May/Jun 2020
Pg. 229
Prednisolone 1 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jan/Feb 2005
Pg. 82-86
Stability of an Extemporaneously Compounded Propylthiouracil Suspension
Author(s): Alexander Kenneth S, Mitra Pallabi
Sep/Oct 2015
Pg. 420-427
Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF
Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul
Mar/Apr 2020
Pg. 136
Quinidine Sulfate 10 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Mar/Apr 2020
Pg. 137
Terbinafine 25 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Mar/Apr 2020
Pg. 138
Topiramate 5 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Mar/Apr 2020
Pg. 130
Acetazolamide 25 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Mar/Apr 2020
Pg. 133
Minocycline Hydrochloride 10 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Mar/Apr 2020
Pg. 134
Nitrofurantoin 2 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Jan/Feb 2004
Pg. 46-48
Basics of Compounding for Disorders of the External Ear
Author(s): Allen Loyd V Jr
Jul/Aug 2019
Pg. 281-287
Mean Kinetic Temperature for Controlled Room Temperature Drug Storage: Official Definitions and Example Calculations
Author(s): Newton David W
Sep/Oct 2021
Pg. 417
Haloperidol 0.5-mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 327-336
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Jul/Aug 2020
Pg. 315
Hydrocortisone Hemisuccinate 2 mg/mL or Hydrocortisone Sodium Phosphate 2 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr